MIG
ALXN

Mariner Investment Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Mariner Investment Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-15,000
Closed -$41K – 237
2015
Q3 		$41K Sell
15,000
-35,000
-70% -$6.38M 0.01% 174
2015
Q2 		$569K Buy
50,000
+20,300
+68% +$3.5M 0.15% 132
2015
Q1 		$51K Buy
+29,700
New +$5.38M 0.01% 153
2014
Q4 		– Sell
-15,000
Closed -$14K – 320
2014
Q3 		$14K Buy
+15,000
New +$2.46M ﹤0.01% 229

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Mariner Investment Group's ALXN Position: Q3 2016 in Review

Mariner Investment Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2016, closing a stake of 54,000 shares — an estimated $6.3M sold.

Mariner Investment Group first reported a position in ALXN in Q1 2014 and held it in 10 quarters. The position peaked at $6.3M in Q2 2016. 518 funds tracked by Wall St. Rank hold ALXN as of Q3 2016.

  • Mariner Investment Group reported no remaining Alexion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Mariner Investment Group sold 54,000 Alexion Pharmaceuticals shares in Q3 2016, an estimated $6.3M.
  • Mariner Investment Group first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 10 quarters.
  • Mariner Investment Group's Alexion Pharmaceuticals position peaked at $6.3M in Q2 2016.
  • 518 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2016.

Based on Mariner Investment Group's 13F filing for Q3 2016, filed 3 Nov 2016.